Home » CEO: Generic Makers Must Turn to Biosimilars Market to Profit
CEO: Generic Makers Must Turn to Biosimilars Market to Profit
Unless generic-drug companies begin investing in biosimilars, they reisk missing profits in an increasingly uncertain small-molecule market, a generic-drug company executive advises.
Generic Line
Generic Line
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May